Lipoic acid offers no improvements in walking speed or other outcomes in patients with progressive multiple sclerosis ...

—Data from this real-world study revealed that patients with MS being treated with DMTs had a disproportionally higher number of cases of herpes zoster compared with patients treated with other ...

Dr. Parisa Khosravi knows exactly what her patients are going through and the shock they might experience when she delivers the diagnosis. As a neuroimmunologist at Central Texas Neurology Consultants ...

An American neurologist and an Italian epidemiologist whose work revolutionized the treatment of multiple sclerosis have won ...

Annual out-of-pocket treatment costs for multiple sclerosis increased by 125% from 2002 to 2021 in the US, driven mainly by ...

Sanofi SNY announced that the FDA has issued a complete response letter (CRL) to its new drug application (NDA), seeking ...

Multiple sclerosis (MS) is a chronic autoimmune disease characterized by the disruption of nerve signals and various ...

Sanofi’s multiple sclerosis hopeful tolebrutinib faced dual setbacks on Monday, with a late-stage failure in one form of the disease and yet another regulatory setback in another.

Brazilian researchers, in partnership with French institutions, have developed a tool that can predict how patients will respond to natalizumab, one of the most commonly used drugs for treating ...

Sanofi will conduct an impairment test in accordance with IFRS (IAS 36) on the intangible asset value attached to tolebrutinib with a status to be provided with Q4 and FY 2025 results in January 2026.